Pancreatic Cancer

by OncoDNA

The FDA will discuss this month an application for approval of the PARP inhibitor olaparaib as maintenance therapy for patients with BRCA-mutant cancer post upfront chemotherapy

Read more

Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors

by Myriad Genetics Iberia

Myriad is actively collaborating with leading pharmaceutical companies to develop Tumor BRACAnalysis CDx as a companion diagnostic for use with certain PARP inhibitors, platinum-based drugs and other ...

Read more
Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Horizon pone en marcha una planta punter...

by Horizon Products

Horizon ha puesto en funcionamiento una nueva planta dedicada íntegra...

Photos Stream